KZA

This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.

Asset Logo

Kazia Therapeutics Limited

🇦🇺 ASX

NULL STOCK

👑 Overview

📈 Performance

💵 Cost

🤓 Advanced

👨‍👩‍👧‍👦 Community

📈

N/A
Annual Growth

5 years average annual growth

💵

$ 500
Minimum Order

Due to regulatory requirements

🌏

1
Pearlers Invested

Since January 2020

👑 Overview

Key information
🔎 Fund Overview

Kazia Therapeutics Ltd. is a clinical stage oncology company It engages in the pharmaceutical research and development business. The company is headquartered in Sydney, New South Wales. The firm is engaged in pharmaceutical research and development. The Company’s drug candidates are designed to treat diseases such as brain cancer, renal cancer, and liver cancer. The Company’s lead programs include paxalisib and EVT801. Paxalisib is a small molecule, brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, a central regulator of growth and cell division that is dysregulated in many types of cancer. Paxalisib is being developed for several forms of brain cancer. EVT801 is a small molecule inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3). EVT801 is being developed in patients with advanced cancer. EVT801 targets angiogenesis, the formation of new blood vessels around a tumor.

📈 Performance

Price History

-63.70%

1M

10Y

Graph

Table

Unsure how much or often to invest?
🗓️ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out →
💵 Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out →
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out →

💵 Costs

💵

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

💼

N/A
Management Fee

Included in unit price, not charged by Pearler

💸

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator

🤓 Advanced information

Technical Info

💰 Price*

$0.08

*Price may be up to 24 hours old

👩‍👩‍👦 Community Insights

How our community is investing

🌏 Pearlers invested in KZA

0

📊 Total Capital Earnings

$-437.588

🔃 Average investment frequency

12 weeks

💵 Average investment amount

$320

Last time a customer invested in KZA

496 days
KZA investor breakdown
💵 Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

Less than 50k

👶 Age of investors

18 - 25

26 - 34

35 - 90

🙋 Legal gender of investors

Female

Male

Pearlers who invest in KZA also invest in...

Anson Resources Limited

ASN

Anson Resources Ltd. is an exploration company, which engages in iron sand mining activities. The company is headquartered in Brisbane, Queensland. The company went IPO on 2010-07-08. Its core asset is the Paradox Lithium Project, which is an advanced development project, covering an area of 167 square kilometers (km2) in the Paradox Basin in southern Utah, in the United States. The company is focused on developing the Paradox Project into a significant lithium producing operation. Its other projects include Green River Lithium Project, Yellow Cat Uranium- Vanadium Project, and Western Australian Exploration Projects. The Western Australian Exploration Projects include Bull Nickel-Copper-PGE Project, Ajana Project, and Hooley Well Cobalt-Nickel Laterite Project. Green River Lithium Project is located 50 kilometers (km) northwest of its Paradox Lithium Project. Yellow Cat Project is located 30 km north of the city Moab, in the Thompson District of Utah, United States. Ajana Project is in the mid-west region of Western Australia.

🙌 Performance (5Yr p.a)

23.33%

📊 Share price

$0.07 AUD

⛏️ MINING

📈 HIGH PRICE GROWTH

Find Out More

Archer Materials Ltd. is a materials technology company, which engages in the developing advanced semiconductor devices and processor chips related to quantum computing and medical diagnostics in Australia. The company is headquartered in Adelaide, South Australia. The company went IPO on 2007-08-14. The company is engaged in developing advanced semiconductor devices, including chips relevant to quantum computing and medical diagnostics. Its principal activities include technology development, including its quantum computing qubit processor chip (12CQ chip) and lab-on-a-chip biochip technology and utilizing semiconductor technology development infrastructure and facilities, research, and development to support research activities. The company focuses on advancing quantum computing and miniaturizing medical labs onto a chip. The company designs and integrates materials for operating qubits in quantum technologies and building graphene transistors for enhanced biosensing. Its development spans qubit processors for practical quantum computing technology, and lab-on-a-chip biosensors for integrated bioelectronics. The company develops its biochip for digitizing biologically relevant signals like those from viruses.

🙌 Performance (5Yr p.a)

18.82%

📊 Share price

$0.33 AUD

📈 HIGH PRICE GROWTH

🤖 TECHNOLOGY

Botanix Pharmaceuticals Ltd. is a dermatology company, which engages in the business of researching and developing dermatology and antimicrobial products. The company is headquartered in Perth, Western Australia. The firm is engaged in the development and commercialization of treatments for common skin diseases and infections. Its lead product is Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis. The company also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea, dermatitis, and acne respectively. The company also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis. Its BTX1503 product is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX1702 product for the treatment of papulopustular rosacea. Its BTX 1204A canine study in Australia and New Zealand for atopic dermatitis. Its BTX1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus.

🙌 Performance (5Yr p.a)

93.64%

📊 Share price

$0.50 AUD

📦 LOGISTICS

BPH Energy Ltd. engages in investments in biotechnology and oil and gas exploration entities. The company is headquartered in Perth, Western Australia. The company went IPO on 2004-08-06. The firm holds a significant interest in an unlisted oil and gas exploration company. The Company’s principal activities include investments in various companies, which include Clean Hydrogen Technologies Corporation (Clean Hydrogen Technologies), Cortical Dynamics Limited (Cortical), Advent Energy Limited, and Molecular Discovery Systems Limited (MDSystems). Clean Hydrogen Technologies is a USA Delaware registered company with technology to produce clean hydrogen. The Advent Energy Limited is an unlisted oil and gas exploration and production company based in Perth, Western Australia. The Cortical is a medical device company focused on developing brain function monitors by employing theories and technologies in the field. MDSystems focuses on drug discovery and the validation of biomarkers for disease, therapy and diagnostics.

🙌 Performance (5Yr p.a)

180.00%

📊 Share price

$0.01 AUD

💸 FINANCIALS

ESGI.AX was created on 2018-03-06 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to provide investment returns before fees and other costs which track the performance of its Reference Index in Australian dollars.

🙌 Performance (5Yr p.a)

8.09%

📊 Share price

$36.77 AUD

🤖 TECHNOLOGY

📈 HIGH PRICE GROWTH

🌏 GLOBAL

Want more shares? Try these...

Kinatico Ltd. engages in the provision of screening and verification services. The company is headquartered in Perth, Western Australia. The company went IPO on 2015-09-08. The Company’s solutions comprise pre-employment screening, verification services and workforce compliance management internationally. The company provides real-time workforce compliance management via its core software-as-a-service RegTech solution Cited. By combining certifications and compliance data with business policy and legislative requirements, Cited enables scalable compliance monitoring spanning pre-employment to real-time requirements related to geo-location, roles and tasks applicable across a range of industries. The company also provides a range of pre-employment checks via its CVCheck solution. This is delivered via its technology platform, which include employment screening and verification offering. Its OnCite is a native mobile application available in iOS and Android, that allows workers to manage their own compliance daily, control their own credentials, and share that information.

🙌 Performance (5Yr p.a)

11.00%

📊 Share price

$0.15 AUD

📈 HIGH PRICE GROWTH

🤖 TECHNOLOGY